When treat­ing Alzheimer’s, ear­li­er is bet­ter, ac­cord­ing to analy­sis of Lil­ly and Ei­sai tri­als

The drug­mak­ers be­hind the new class of Alzheimer’s treat­ments are co­a­lesc­ing around a com­mon nar­ra­tive: When it comes to slow­ing the dis­ease, the ear­li­er a pa­tient is treat­ed, the bet­ter.

Ei­sai and Eli Lil­ly each took to the stage of the sold-out Clin­i­cal Tri­als on Alzheimer’s Dis­ease con­fer­ence in Boston on Wednes­day with cuts of da­ta from their large piv­otal stud­ies look­ing at how sub­sets of pa­tients in the tri­al re­spond­ed to treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER